Cyrus Khan
About
Cyrus Khan is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Cyrus Khan has authored 44 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pathology and Forensic Medicine, 27 papers in Oncology and 9 papers in Genetics. Recurrent topics in Cyrus Khan's work include Lymphoma Diagnosis and Treatment (27 papers), CAR-T cell therapy research (16 papers) and CNS Lymphoma Diagnosis and Treatment (9 papers). Cyrus Khan is often cited by papers focused on Lymphoma Diagnosis and Treatment (27 papers), CAR-T cell therapy research (16 papers) and CNS Lymphoma Diagnosis and Treatment (9 papers). Cyrus Khan collaborates with scholars based in United States, Switzerland and Italy. Cyrus Khan's co-authors include John Lister, Salman Fazal, James M. Rossetti, Monica Tani, Franck Morschhauser, Carmelo Carlo‐Stella, Martin Hutchings, Linda Lundberg, Emmanuel Bachy and James Relf and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Thorax.
In The Last Decade
Cyrus Khan
37 papers receiving 273 citations
Peers
Cyrus Khan
S. Grisanti Italy
Bryan Do United States
Ana Jiménez Ubieto Spain
Dejan Radeski Australia
Takaaki Chou Japan
Michelle Poon Singapore
Rodica Morariu-Zamfir United States
Harry Miao United States
Michael Fennessy United Kingdom
Bérengère Vire United States
Citations per year, relative to Cyrus Khan Cyrus Khan (= 1×)
peers
S. Grisanti
Countries citing papers authored by Cyrus Khan
Since
Specialization
Citations
This map shows the geographic impact of Cyrus Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cyrus Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cyrus Khan more than expected).
Fields of papers citing papers by Cyrus Khan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Cyrus Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cyrus Khan. The network helps show where Cyrus Khan may publish in the future.
Co-authorship network of co-authors of Cyrus Khan
This figure shows the co-authorship network connecting the top 25 collaborators of Cyrus Khan. A scholar is included among the top collaborators of Cyrus Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cyrus Khan. Cyrus Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Leening, Maarten J.G., Cyrus Khan, Fang Zhu, et al.. (2025). Lipoprotein(a) immunoassays and their associations with coronary artery calcification and aortic valve calcification. American Heart Journal. 284. 42–46.
2.
Falchi, Lorenzo, Martin Hutchings, Carmelo Carlo‐Stella, et al.. (2024). Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma. Haematologica. 110(4). 999–1004.
3.
Bunker, Mark, et al.. (2024). Successful Treatment of Refractory Post-Transplant Lymphoproliferative Disorder With Chimeric Antigen Receptor T-Cell Therapy in a Heart Transplant Recipient. Journal of Hematology. 13(1-2). 34–38.
4.
Hutchings, Martin, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2024). ABCL-340 Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume. Clinical Lymphoma Myeloma & Leukemia. 24. S473–S473.
5.
Jayakrishnan, Thejus, et al.. (2023). Treatment Selection and Survival in Patients with Gray Zone Lymphoma: A Comprehensive Population-Based Analysis. Hematology/Oncology and Stem Cell Therapy. 16(3). 245–253.
6.
Falchi, Lorenzo, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2023). Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.. Journal of Clinical Oncology. 41(16_suppl). 7550–7550.
7.
Dickinson, Michael, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2023). GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY. Hematological Oncology. 41(S2). 144–146.
8.
Khan, Cyrus, et al.. (2023). Likelihood of Successful Mobilization with Cyclophosphamide after Failure of Growth Factor Mobilization in Patients with Multiple Myeloma. Transplantation and Cellular Therapy. 29(2). S182–S183.
9.
Khan, Cyrus, et al.. (2023). A Meningioma Mimic and Distinct Subtype of Primary Central Nervous System Lymphoma: Primary Dural Lymphoma. Journal of Hematology. 12(2). 87–91.
10.
Khan, Cyrus, et al.. (2023). Primary Testicular Lymphoma: Single Center Experience. Cancer Diagnosis & Prognosis. 3(2). 139–144.
11.
Ali, Moaath K. Mustafa, et al.. (2022). The Trend of Combined Modality Treatment and its Outcomes in Elderly Patients With Primary CNS Lymphoma: A 12-year Population-based Analysis Using Propensity Score. Anticancer Research. 42(4). 1867–1877.
12.
Ali, Moaath K. Mustafa, Jennie Y. Law, Cyrus Khan, et al.. (2022). Consolidative Autologous Stem Cell Transplantation Versus Whole Brain Radiation in PCNSL; a Nationwide Analysis. Clinical Lymphoma Myeloma & Leukemia. 22(10). 735–743.
13.
Ali, Moaath K. Mustafa, Jennie Y. Law, Cyrus Khan, et al.. (2022). Patterns of treatment and their outcomes in primary breast lymphoma; a comprehensive population-based analysis. Breast Cancer. 29(6). 1022–1031.
14.
Khan, Cyrus, et al.. (2022). Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome. Anticancer Research. 42(8). 3853–3856.
15.
Dickinson, Michael, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2021). Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts). Blood. 138(Supplement 1). 2478–2478.
16.
Carlo‐Stella, Carmelo, Cyrus Khan, Martin Hutchings, et al.. (2021). ABCL-360: Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts). Clinical Lymphoma Myeloma & Leukemia. 21. S394–S394.
17.
Ali, Moaath K. Mustafa, Thejus Jayakrishnan, Salman Fazal, et al.. (2021). Autologous stem cell transplantation (ASCT) versus whole brain radiation (WBRT) as a consolidation therapy in primary CNS lymphoma (PCNSL): A nationwide analysis.. Journal of Clinical Oncology. 39(15_suppl). 2062–2062.
18.
Younes, Anas, John M. Burke, Bruce D. Cheson, et al.. (2019). Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study. Blood. 134(Supplement_1). 2874–2874.
19.
Younes, Anas, John M. Burke, Bruce D. Cheson, et al.. (2018). Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study. Blood. 132(Supplement 1). 2969–2969.
20.
Friderici, Jennifer, et al.. (2012). Effectiveness of varenicline for smoking cessation at 2 urban academic health centers. European Journal of Internal Medicine. 23(5). 461–464.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by S. Grisanti Breakdown of academic impact, for papers by Bryan Do Breakdown of academic impact, for papers by Ana Jiménez Ubieto Breakdown of academic impact, for papers by Dejan Radeski Breakdown of academic impact, for papers by Takaaki Chou Breakdown of academic impact, for papers by Michelle Poon Breakdown of academic impact, for papers by Rodica Morariu-Zamfir Breakdown of academic impact, for papers by Harry Miao Breakdown of academic impact, for papers by Michael Fennessy Breakdown of academic impact, for papers by Bérengère Vire